Overnight Health Care: US buying additional 200M Moderna vaccine doses | CureVac's COVID-19 vaccine failed in preliminary trial results | Grassley meets with House Dems on drug prices

Overnight Health Care: US buying additional 200M Moderna vaccine doses | CureVac's COVID-19 vaccine failed in preliminary trial results | Grassley meets with House Dems on drug prices
© getty

Welcome to Wednesday's Overnight Health Care. COVID-19 strikes at the NBA playoffs: Phoenix Suns star Chris Paul is in danger of missing games after entering the league’s virus health and safety protocol, though details are unclear. 

If you have any tips, email us at  nweixel@thehill.com psullivan@thehill.com jcoleman@thehill.com

Follow us on Twitter at @NateWeixel, @PeterSullivan4, and @JustineColeman8. 

ADVERTISEMENT

Today: The U.S. is buying even more doses of Moderna's coronavirus vaccine, a Gates Foundation-funded COVID-19 vaccine attempt failed, a federal appeals court struck down North Carolina's long-standing abortion restrictions, and House Democrats huddled with Sen. Chuck GrassleyChuck GrassleyAxne endorses Finkenauer Senate bid in Iowa Seven-figure ad campaign urges GOP to support infrastructure bill Biden names new watchdog at finance agency after embattled IG departs MORE to talk drug pricing reform.

We'll start with vaccines:

US buying additional 200M Moderna vaccine doses

The U.S. government is buying another 200 million doses of Moderna’s COVID-19 vaccine, the company said Wednesday, which could be used for vaccinating children or to address variants of the virus if necessary.  

Why are more needed? The deal allows the Biden administration to receive different versions of the vaccine if necessary, for example if a modified vaccine is needed to fight a variant of the virus. The purchase is exercising an option for additional doses from the original contract with Moderna. 

"Importantly, the agreement gives the United States flexibility to choose which type of vaccine we will receive from Moderna if Moderna adjusts its formulation, for example, for pediatric vaccines or to address variants," an administration official said. 

“We appreciate the collaboration with the U.S. government for these additional doses of the Moderna COVID-19 vaccine, which could be used for primary vaccination, including of children, or possibly as a booster if that becomes necessary to continue to defeat the pandemic,” Moderna CEO Stéphane Bancel said in a statement. “We remain focused on being proactive as the virus evolves by leveraging the flexibility of our mRNA platform to stay ahead of emerging variants.”

ADVERTISEMENT

Read more here.

 

CureVac's COVID-19 vaccine failed in preliminary trial results

A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants.

The company's 40,000 person trial was conducted in 10 countries in Latin America and Europe, where "at least" 13 different variants were circulating. The 47 percent efficacy result, while not final, is the lowest reported to date from any COVID-19 vaccine manufacturer.

CureVac is backed by the Bill & Melinda Gates Foundation, which invested $52 million. Its vaccine relies on mRNA technology, similar to what is used in the successful Pfizer-BioNTech and Moderna vaccines.

Read more here. 

 

Grassley meets with moderate House Democrats on lowering drug prices 

Sen. Chuck Grassley (R-Iowa) met on Wednesday with a group of moderate House Democrats to see if there is a way forward for a bipartisan approach to lowering prescription drug prices. 

The meeting took place in the office of Rep. Stephanie MurphyStephanie MurphyLawmakers can't reconcile weakening the SALT cap with progressive goals Select committee member thanks officers who responded Jan. 6: 'You were our last line of defense' House erupts in anger over Jan. 6 and Trump's role MORE (D-Fla.), one of the leaders of the moderate Blue Dog Coalition, according to a House Democratic aide. It included some of the 10 Democratic lawmakers who had signed a letter in May signaling concerns with the sweeping drug pricing bill backed by House Democratic leaders, known as H.R. 3, and calling instead for a bipartisan approach that would preserve innovation from drug companies.  

There were a total of five House Democrats in the meeting, in addition to Grassley, the aide said.  

Rep. Kurt SchraderWalter (Kurt) Kurt SchraderModerate Democrats call for 9/11-style panel to probe COVID-19 origins Overnight Health Care: White House signals new COVID-19 strategy as delta variant spreads | McConnell urges vaccinations | Maryland says all COVID-19 deaths last month were among unvaccinated Democrats eye next stage of spending fight MORE (D-Ore.), who attended the meeting, told The Hill the group was “just trying to figure out: Can we move something forward?” 

Asked if the group could come up with an alternative to H.R. 3, Schrader replied, “we’re finding that out.”

Tough road for a bipartisan approach, though: That’s because many Democratic lawmakers, including leadership, are intent on including a provision to allow Medicare to negotiate lower prices, saying that is needed to get meaningful savings. Almost all Republican lawmakers oppose that idea. 

Read more here

 

WHO says Delta COVID-19 variant has spread to at least 80 countries

The World Health Organization (WHO) declared on Wednesday that the highly transmissible Delta variant has been confirmed to have spread to more than 80 countries. 

The count represents a boost from last week when WHO said the variant had spread to at least 74 countries.

The Delta strain, originally detected in India, is thought to be around 60 percent more contagious than the previously detected Alpha strain, first found in the U.K. 

ADVERTISEMENT

Background: The variant, which is also known by the scientific name B.1.617.2, now makes up 10 percent of all COVID-19 infections in the U.S. – up from the estimated more than 6 percent last week  

The Delta strain became the dominant variant in the U.K. earlier this month, overtaking the Alpha variant. Last week, the U.K. reported a 240 percent increase in Delta variant cases in seven days, leading the strain to make up more than 90 percent of all cases.

Follows: The CDC labeled the Delta variant as a “variant of concern” on Tuesday after concerns have mounted about the strain causing outbreaks among unvaccinated people in the U.S. 

But the Pfizer-BioNTech and Moderna vaccines, which are both mRNA vaccines, are about 88 percent effective against the variant. 

Read more here.

 

Appeals court affirms North Carolina's 20-week abortion ban is unconstitutional

ADVERTISEMENT

North Carolina's decades-old ban on abortions after 20 weeks is unconstitutional, a federal appeals court found on Wednesday.

The decision from the U.S. Court of Appeals for the 4th Circuit affirms the decision of a lower court, which first struck down the ban two years ago.

It has been a felony in North Carolina for the past 140 years to procure or administer an abortion, but following the Supreme Court's Roe v. Wade ruling in 1973, the law was amended to bar abortions after 20 weeks, with exemptions for medical emergencies.

The lawsuit was filed by a group of abortion providers and advocates in 2015, after the state legislature narrowed the medical exemption and further restricted the type of doctors permitted to perform abortions to "qualified physicians."

The amendments also instituted a 72-hour waiting period that women must observe before obtaining an abortion.

Read more here

 

Regeneron antibody cocktail cut COVID-19 deaths in some cases: research

Oxford University on Wednesday released a study that found that a COVID-19 antibody cocktail created by Regeneron reduces the risk of death due to the coronavirus.

The treatment known as REGEN-COV, which was granted emergency use authorization in the U.S. in November, was found to be able to neutralize the COVID-19 virus's ability to infect cells. The treatment uses a combination of the monoclonal antibodies casirivimab and imdevimab.

Of the patients that were observed in the study, the Regeneron cocktail reduced mortality by one-fifth among patients who were seronegative — had not developed an antibody response to the virus yet — when compared to similar patients who received normal care.

The researchers estimated, based on their observations, that treatment with Regeneron would result in six fewer deaths for every 100 patients who received the cocktail.

Read more here

 

What we’re reading

Royal Caribbean's launch of its new megaship just got sidelined by COVID cases (NPR)

Lifelong exercise adds up to big health care savings (The New York Times

The science around the lab leak theory hasn't changed. But here's why some scientists have. (NBC News)

Temp checks, digital menus and ‘touchless’ mustard: The maddening persistence of ‘hygiene theater’ (Washington Post)

 

State by state 

Coronavirus vaccination gap remains for some groups in Mass., state officials say (The Boston Globe

Test Iowa program to end in July as demand for coronavirus tests wanes (Des Moines Register

Missouri Medicaid expansion trial begins Friday (KPVI

 

Op-eds in The Hill

We're re-opening, but pandemic social costs will linger